Hani Gabra

Founder at Papyrus Therapeutics, Inc.

Health Technology

Consumer Services

Commercial Services

Profile

Hani Gabra is the founder of Papyrus Therapeutics, Inc. He is currently a Professor at Imperial College London.
He previously worked as the Director of Clinical Development at BerGenBio ASA from 2021 to 2022 and as the Vice President of Early Clinical Development at AstraZeneca PLC.

Hani Gabra active positions

Companies	Position	Start
Imperial College London	Corporate Officer/Principal	-
Papyrus Therapeutics, Inc. Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.	Founder	-

All active positions of Hani Gabra

Former positions of Hani Gabra

Companies	Position	End
BERGENBIO ASA	Chief Tech/Sci/R&D Officer	-
ASTRAZENECA PLC	Corporate Officer/Principal	-

See the detail of Hani Gabra's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Hani Gabra's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ASTRAZENECA PLC	Health Technology
BERGENBIO ASA	Health Technology

Private companies	1
Papyrus Therapeutics, Inc. Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.	Commercial Services